AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Investing.com -- AstraZeneca (LON: AZN ) (ST: AZN) shares fell more than 3% Tuesday after the drugmaker missed first-quarter revenue expectations, with underperformance in key cancer and respiratory ...

AstraZeneca’s AZN first-quarter 2025 core earnings of $1.24 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.10. Core earnings of $2.49 per share rose 21% year over year on ...

Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West ...

SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal biologic drug for Iconovo's proprietary intranasa ...

Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot ...

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...